{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:12:37Z","timestamp":1767993157721,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA095426"],"award-info":[{"award-number":["P01 CA095426"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 GM068412"],"award-info":[{"award-number":["T32 GM068412"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00262-016-1893-7","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T22:14:24Z","timestamp":1472854464000},"page":"1353-1364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-\u03b1-2b in patients with CEA-expressing carcinomas"],"prefix":"10.1007","volume":"65","author":[{"given":"Megan C.","family":"Duggan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Jochems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee N.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volodymyr","family":"Karpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Foust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susheela","family":"Tridandapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Olencki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueliang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory B.","family":"Lesinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Carson III","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"key":"1893_CR1","unstructured":"American Cancer Society (2016) Key statistics for colorectal cancer. Am Cancer Soc. http:\/\/www.cancer.org\/cancer\/colonandrectumcancer\/detailedguide\/colorectal-cancer-key-statistics. Accessed 24 Mar 2016"},{"key":"1893_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11894-002-0013-3","volume":"4","author":"A Demols","year":"2002","unstructured":"Demols A, Van Laethem J-L (2002) Adjuvant chemotherapy for colorectal cancer. Curr Gastroenterol Rep 4:420\u2013426","journal-title":"Curr Gastroenterol Rep"},{"key":"1893_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clcc.2014.11.002","volume":"14","author":"B Gustavsson","year":"2015","unstructured":"Gustavsson B, Carlsson G, Machover D et al (2015) A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 14:1\u201310. doi:10.1016\/j.clcc.2014.11.002","journal-title":"Clin Colorectal Cancer"},{"key":"1893_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/1471-2407-14-521","volume":"14","author":"G Folprecht","year":"2014","unstructured":"Folprecht G, Hamann S, Sch\u00fctte K et al (2014) Dose escalating study of cetuximab and 5-FU\/folinic acid (FA)\/oxaliplatin\/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. BMC Cancer 14:521. doi:10.1186\/1471-2407-14-521","journal-title":"BMC Cancer"},{"key":"1893_CR5","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.3748\/wjg.v20.i30.10425","volume":"20","author":"AM Marques","year":"2014","unstructured":"Marques AM, Turner A, de Mello RA (2014) Personalizing medicine for metastatic colorectal cancer: current developments. World J Gastroenterol 20:10425\u201310431. doi:10.3748\/wjg.v20.i30.10425","journal-title":"World J Gastroenterol"},{"key":"1893_CR6","first-page":"227","volume":"695","author":"GT Rogers","year":"1983","unstructured":"Rogers GT (1983) Carcinoembryonic antigens and related glycoproteins. Molecular aspects and specificity. Biochim Biophys Acta 695:227\u2013249","journal-title":"Biochim Biophys Acta"},{"key":"1893_CR7","first-page":"5769","volume":"45","author":"R Muraro","year":"1985","unstructured":"Muraro R, Wunderlich D, Thor A et al (1985) Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 45:5769\u20135780","journal-title":"Cancer Res"},{"key":"1893_CR8","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/1097-0142(197405)33:5<1246::AID-CNCR2820330509>3.0.CO;2-O","volume":"33","author":"AM Steward","year":"1974","unstructured":"Steward AM, Nixon D, Zamcheck N, Aisenberg A (1974) Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer 33:1246\u20131252","journal-title":"Cancer"},{"key":"1893_CR9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0022-5223(19)40638-7","volume":"66","author":"RG Vincent","year":"1973","unstructured":"Vincent RG, Chu TM (1973) Carcinoembryonic antigen in patients with carcinoma of the lung. J Thorac Cardiovasc Surg 66:320\u2013328","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1893_CR10","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/clinchem\/26.8.1213","volume":"26","author":"JH Ladenson","year":"1980","unstructured":"Ladenson JH, McDonald JM, Landt M, Schwartz MK (1980) Washington University Case Conference). Colorectal carcinoma and carcinoembryonic antigen (CEA). Clin Chem 26:1213\u20131220","journal-title":"Clin Chem"},{"key":"1893_CR11","first-page":"5800","volume":"59","author":"JW Hodge","year":"1999","unstructured":"Hodge JW, Sabzevari H, Yafal AG et al (1999) A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 59:5800\u20135807","journal-title":"Cancer Res"},{"key":"1893_CR12","first-page":"4570","volume":"57","author":"S Zaremba","year":"1997","unstructured":"Zaremba S, Barzaga E, Zhu M et al (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570\u20134577","journal-title":"Cancer Res"},{"key":"1893_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<829::AID-IJC16>3.0.CO;2-K","volume":"85","author":"E Salazar","year":"2000","unstructured":"Salazar E, Zaremba S, Arlen PM et al (2000) Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int J Cancer 85:829\u2013838","journal-title":"Int J Cancer"},{"key":"1893_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/JCO.2005.10.206","volume":"23","author":"JL Marshall","year":"2005","unstructured":"Marshall JL, Gulley JL, Arlen PM et al (2005) Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23:720\u2013731. doi:10.1200\/JCO.2005.10.206","journal-title":"J Clin Oncol"},{"key":"1893_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/BF00199933","volume":"26","author":"F Guadagni","year":"1988","unstructured":"Guadagni F, Schlom J, Pothen S et al (1988) Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol Immunother 26:222\u2013230","journal-title":"Cancer Immunol Immunother"},{"key":"1893_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1126\/science.3580039","volume":"235","author":"JW Greiner","year":"1987","unstructured":"Greiner JW, Guadagni F, Noguchi P et al (1987) Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235:895\u2013898","journal-title":"Science"},{"key":"1893_CR17","first-page":"4984","volume":"46","author":"JW Greiner","year":"1986","unstructured":"Greiner JW, Fisher PB, Pestka S, Schlom J (1986) Differential effects of recombinant human leukocyte interferons on cell surface antigen expression. Cancer Res 46:4984\u20134990","journal-title":"Cancer Res"},{"key":"1893_CR18","first-page":"6248","volume":"50","author":"F Guadagni","year":"1990","unstructured":"Guadagni F, Witt PL, Robbins PF et al (1990) Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma. Cancer Res 50:6248\u20136255","journal-title":"Cancer Res"},{"key":"1893_CR19","first-page":"1639","volume":"9","author":"JA Leon","year":"1989","unstructured":"Leon JA, Mesa-Tejada R, Gutierrez MC et al (1989) Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters. Anticancer Res 9:1639\u20131647","journal-title":"Anticancer Res"},{"key":"1893_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/172460089400900111","volume":"9","author":"F Guadagni","year":"1994","unstructured":"Guadagni F, Roselli M, Schlom J, Greiner JW (1994) In vitro and in vivo regulation of human tumor antigen expression by human recombinant interferons: a review. Int J Biol Markers 9:53\u201360","journal-title":"Int J Biol Markers"},{"key":"1893_CR21","first-page":"3208","volume":"44","author":"JW Greiner","year":"1984","unstructured":"Greiner JW, Hand PH, Noguchi P et al (1984) Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res 44:3208\u20133214","journal-title":"Cancer Res"},{"key":"1893_CR22","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1084\/jem.191.10.1777","volume":"191","author":"SM Santini","year":"2000","unstructured":"Santini SM, Lapenta C, Logozzi M et al (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777\u20131788","journal-title":"J Exp Med"},{"key":"1893_CR23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2326-6066.CIR-15-0119","volume":"3","author":"CR Heery","year":"2015","unstructured":"Heery CR, Singh BH, Rauckhorst M et al (2015) Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury. Cancer Immunol Res 3:1248\u20131256. doi:10.1158\/2326-6066.CIR-15-0119","journal-title":"Cancer Immunol Res"},{"key":"1893_CR24","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/jnci\/87.13.982","volume":"87","author":"KY Tsang","year":"1995","unstructured":"Tsang KY, Zaremba S, Nieroda CA et al (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982\u2013990","journal-title":"J Natl Cancer Inst"},{"key":"1893_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00262-011-1029-z","volume":"60","author":"BL Mundy-Bosse","year":"2011","unstructured":"Mundy-Bosse BL, Young GS, Bauer T et al (2011) Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunol Immunother 60:1269\u20131279. doi:10.1007\/s00262-011-1029-z","journal-title":"Cancer Immunol Immunother"},{"key":"1893_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1893_CR27","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.4049\/jimmunol.1300022","volume":"190","author":"J Huang","year":"2013","unstructured":"Huang J, Jochems C, Anderson AM et al (2013) Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol 190:6250\u20136258. doi:10.4049\/jimmunol.1300022","journal-title":"J Immunol"},{"key":"1893_CR28","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1182\/blood-2012-05-427799","volume":"120","author":"J Huang","year":"2012","unstructured":"Huang J, Jochems C, Talaie T et al (2012) Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 120:3030\u20133038. doi:10.1182\/blood-2012-05-427799","journal-title":"Blood"},{"key":"1893_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162\u2013174. doi:10.1038\/nri2506","journal-title":"Nat Rev Immunol"},{"key":"1893_CR30","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-05-3396","volume":"66","author":"T Di Pucchio","year":"2006","unstructured":"Di Pucchio T, Pilla L, Capone I et al (2006) Immunization of stage IV melanoma patients with Melan-A\/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte\/dendritic cell precursors. Cancer Res 66:4943\u20134951. doi:10.1158\/0008-5472.CAN-05-3396","journal-title":"Cancer Res"},{"key":"1893_CR31","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/ijc.27819","volume":"132","author":"ECM Zeestraten","year":"2013","unstructured":"Zeestraten ECM, Speetjens FM, Welters MJP et al (2013) Addition of interferon-\u03b1 to the p53-SLP\u00ae vaccine results in increased production of interferon-\u03b3 in vaccinated colorectal cancer patients: a phase I\/II clinical trial. Int J Cancer 132:1581\u20131591. doi:10.1002\/ijc.27819","journal-title":"Int J Cancer"},{"key":"1893_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/gastro\/gov053","volume":"3","author":"PP Singh","year":"2015","unstructured":"Singh PP, Sharma PK, Krishnan G, Lockhart AC (2015) Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf) 3:289\u2013297. doi:10.1093\/gastro\/gov053","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"1893_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1053\/j.seminoncol.2012.02.010","volume":"39","author":"RA Madan","year":"2012","unstructured":"Madan RA, Bilusic M, Heery C et al (2012) Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 39:296\u2013304. doi:10.1053\/j.seminoncol.2012.02.010","journal-title":"Semin Oncol"},{"key":"1893_CR34","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1158\/1078-0432.CCR-11-0649","volume":"17","author":"M Mohebtash","year":"2011","unstructured":"Mohebtash M, Tsang K-Y, Madan RA et al (2011) A pilot study of MUC-1\/CEA\/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 17:7164\u20137173. doi:10.1158\/1078-0432.CCR-11-0649","journal-title":"Clin Cancer Res"},{"key":"1893_CR35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/SLA.0b013e318292919e","volume":"258","author":"MA Morse","year":"2013","unstructured":"Morse MA, Niedzwiecki D, Marshall JL et al (2013) A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 258:879\u2013886. doi:10.1097\/SLA.0b013e318292919e","journal-title":"Ann Surg"},{"key":"1893_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/BF01519631","volume":"40","author":"DM Mahvi","year":"1995","unstructured":"Mahvi DM, Madsen JA, Witt PL, Sondel PM (1995) Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer. Cancer Immunol Immunother 40:311\u2013314","journal-title":"Cancer Immunol Immunother"},{"key":"1893_CR37","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/jnci\/81.7.502","volume":"81","author":"F Guadagni","year":"1989","unstructured":"Guadagni F, Schlom J, Johnston WW et al (1989) Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 81:502\u2013512","journal-title":"J Natl Cancer Inst"},{"key":"1893_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jnci\/80.3.160","volume":"80","author":"MG Rosenblum","year":"1988","unstructured":"Rosenblum MG, Lamki LM, Murray JL et al (1988) Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 80:160\u2013165","journal-title":"J Natl Cancer Inst"},{"key":"1893_CR39","first-page":"5925s","volume":"55","author":"JL Murray","year":"1995","unstructured":"Murray JL, Macey DJ, Grant EJ et al (1995) Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Cancer Res 55:5925s\u20135928s","journal-title":"Cancer Res"},{"key":"1893_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","volume":"74","author":"FM Marincola","year":"2000","unstructured":"Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181\u2013273","journal-title":"Adv Immunol"},{"key":"1893_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.191.6.961","volume":"191","author":"LA Koopman","year":"2000","unstructured":"Koopman LA, Corver WE, van der Slik AR et al (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191:961\u2013976","journal-title":"J Exp Med"},{"key":"1893_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00202069","volume":"74","author":"A van de Stolpe","year":"1996","unstructured":"van de Stolpe A, van der Saag PT (1996) Intercellular adhesion molecule-1. J Mol Med (Berl) 74:13\u201333","journal-title":"J Mol Med (Berl)"},{"key":"1893_CR43","first-page":"1500","volume":"61","author":"M Imboden","year":"2001","unstructured":"Imboden M, Murphy KR, Rakhmilevich AL et al (2001) The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 61:1500\u20131507","journal-title":"Cancer Res"},{"key":"1893_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/(SICI)1097-0045(19971201)33:4<233::AID-PROS2>3.0.CO;2-I","volume":"33","author":"NH Bander","year":"1997","unstructured":"Bander NH, Yao D, Liu H et al (1997) MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33:233\u2013239","journal-title":"Prostate"},{"key":"1893_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/BF00353741","volume":"18","author":"C Makridis","year":"1994","unstructured":"Makridis C, Juhlin C, Akerstr\u00f6m G et al (1994) MHC class I and II antigen expression and interferon alpha treatment of human midgut carcinoid tumors. World J Surg 18:481\u2013486","journal-title":"World J Surg"},{"key":"1893_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00262-014-1618-8","volume":"64","author":"J Markowitz","year":"2015","unstructured":"Markowitz J, Brooks TR, Duggan MC et al (2015) Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother 64:149\u2013159. doi:10.1007\/s00262-014-1618-8","journal-title":"Cancer Immunol Immunother"},{"key":"1893_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero CM, Salem ML, Nishimura MI et al (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49\u201359. doi:10.1007\/s00262-008-0523-4","journal-title":"Cancer Immunol Immunother"},{"key":"1893_CR48","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1158\/0008-5472.CAN-10-2670","volume":"71","author":"BL Mundy-Bosse","year":"2011","unstructured":"Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC et al (2011) Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 71:5101\u20135110. doi:10.1158\/0008-5472.CAN-10-2670","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1893-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-016-1893-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1893-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T16:29:21Z","timestamp":1684859361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-016-1893-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1893-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]},"assertion":[{"value":"16 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}